Search Results

Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company, today announces developments in its Phase I/II clinical trial investigating a novel treatment for Type 1 Diabetes (T1D). To date a total of 7 patients across Cohorts 1 and 2 have achieved insulin independence following transplants of human donor islets via Sernova’s proprietary Cell Pouch System™ and a marginal portal vein top up.

A group of longstanding shareholders of Sernova Corp who currently own approximately 12% of the Company’s shares have concerns regarding the performance of Sernova’s Board.

Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced that its Board of Directors has appointed Cynthia Pussinen as Chief Executive Officer and a member of the Board of Directors.

Sernova Corp. today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for the company’s Hemophilia A program.

Sernova Corp. today announced it will host two investor and analyst conference calls, with corresponding live webcasts.

Sernova Corp. announced two oral presentations at the upcoming International Pancreas and Islet Transplant Association, International Xenotransplantation Association Cell Transplant & Regenerative Medicine Association joint congress taking October 26-29, 2023 in San Diego, CA.